[¹⁸F]FDG-PET in Lung Cancer: From Staging to Therapy Response

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Lung cancer is the leading cause of cancer mortality globally.
• Molecular imaging, particularly [18F] 2-Fluoro-2-deoxy-glucose (FDG) PET/CT, is increasingly vital in lung cancer management.
• FDG PET/CT aids in evaluating pulmonary nodules, staging, radiotherapy planning, and assessing treatment response.

Purpose of the Study:

• To review the current utility of FDG PET in non-small-cell lung cancer (NSCLC).
• To discuss the emerging roles of artificial intelligence (AI) and radiogenomics in lung cancer molecular imaging.
• To provide insights into future directions for advanced imaging in NSCLC.

Main Methods:

• Literature review of studies on FDG PET/CT in lung cancer.
• Analysis of current applications of FDG PET in NSCLC diagnosis and management.
• Exploration of AI and radiogenomic integration in molecular imaging.

Main Results:

• FDG PET/CT is a well-established tool for various aspects of lung cancer care.
• AI and radiogenomics show significant promise for enhancing diagnostic accuracy and personalized treatment in NSCLC.
• Integration of these technologies could revolutionize lung cancer imaging.

Conclusions:

• FDG PET/CT remains a cornerstone in lung cancer management.
• Artificial intelligence and radiogenomics represent the future frontier for molecular imaging in NSCLC, offering potential for improved patient outcomes.
• Further research is warranted to fully integrate these advanced techniques into clinical practice.